Literature DB >> 23331647

Clinical Policy: Use of intravenous tPA for the management of acute ischemic stroke in the emergency department.

.   

Abstract

This policy was developed by a joint writing panel of the American College of Emergency Physicians and the American Academy of Neurology. The panel reviewed the literature to derive evidence-based recommendations to help clinicians answer the following critical questions: (1) Is intravenous tissue plasminogen activator (tPA) safe and effective for acute ischemic stroke patients if given within 3 hours of symptom onset? (2) Is intravenous tPA safe and effective for acute ischemic stroke patients treated between 3 to 4.5 hours after symptom onset? Evidence was graded and recommendations were given based on the strength of the available data in the medical literature.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23331647     DOI: 10.1016/j.annemergmed.2012.11.005

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  17 in total

1.  Why don't more patients receive intravenous rt-PA for acute stroke?

Authors:  Patrick Lyden
Journal:  Expert Rev Neurother       Date:  2015-05-04       Impact factor: 4.618

2.  Trans-sodium crocetinate improves outcomes in rodent models of occlusive and hemorrhagic stroke.

Authors:  Yi Wang; Ryo Yoshimura; Hiroaki Manabe; Catherine Schretter; Ryon Clarke; Yu Cai; Mark Fitzgerald; Kevin S Lee
Journal:  Brain Res       Date:  2014-08-14       Impact factor: 3.252

3.  Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument.

Authors:  David M Kent; Robin Ruthazer; Carole Decker; Philip G Jones; Jeffrey L Saver; Erich Bluhmki; John A Spertus
Journal:  Neurology       Date:  2015-08-19       Impact factor: 9.910

4.  Airway tissue plasminogen activator prevents acute mortality due to lethal sulfur mustard inhalation.

Authors:  Livia A Veress; Dana R Anderson; Tara B Hendry-Hofer; Paul R Houin; Jacqueline S Rioux; Rhonda B Garlick; Joan E Loader; Danielle C Paradiso; Russell W Smith; Raymond C Rancourt; Wesley W Holmes; Carl W White
Journal:  Toxicol Sci       Date:  2014-10-20       Impact factor: 4.849

5.  Getting the Gist Across Is Enough for Informed Consent for Acute Stroke Thrombolytics.

Authors:  Lesli E Skolarus; Alison O'Brien; William J Meurer; Brian J Zikmund Fisher
Journal:  Stroke       Date:  2019-05-14       Impact factor: 7.914

6.  Predictors of in-hospital mortality and dependence at discharge in patients with MCA stroke with intravenous thrombolysis.

Authors:  Renata Dal-Prá Ducci; Marcos Christiano Lange; Viviane de Hiroki Flumignan Zétola
Journal:  Intern Emerg Med       Date:  2016-12-27       Impact factor: 3.397

Review 7.  Alteplase in acute ischemic stroke: putting the guidelines into practice.

Authors:  Nandakumar Nagaraja; Harold P Adams
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 8.  Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

Authors:  Gyanendra Kumar; Drew Uhrig; Susan Fowler; Matthew C DeLaney; Andrei V Alexandrov
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

9.  Model-based assessment of the benefits and risks of recombinant tissue plasminogen activator treatment in acute ischaemic stroke.

Authors:  Jinju Guk; Dongwoo Chae; Hankil Son; Joonsang Yoo; Ji Hoe Heo; Kyungsoo Park
Journal:  Br J Clin Pharmacol       Date:  2018-08-21       Impact factor: 4.335

10.  Emergence of the primary pediatric stroke center: impact of the thrombolysis in pediatric stroke trial.

Authors:  Timothy J Bernard; Michael J Rivkin; Kelley Scholz; Gabrielle deVeber; Adam Kirton; Joan Cox Gill; Anthony K Chan; Collin A Hovinga; Rebecca N Ichord; James C Grotta; Lori C Jordan; Susan Benedict; Neil R Friedman; Michael M Dowling; Jorina Elbers; Marcela Torres; Sally Sultan; Dana D Cummings; Eric F Grabowski; Hugh J McMillan; Lauren A Beslow; Catherine Amlie-Lefond
Journal:  Stroke       Date:  2014-06-10       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.